SAN FRANCISCO, March 22, 2017 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") announced today that it has entered into a license agreement with Magenta Therapeutics, Inc. to grant access to The Trianni Mouse, a best-in-class monoclonal antibody discovery platform. The platform will be made available to Magenta through one of TRIANNI's approved Contact Research Organization providers.
"Trianni is delighted to add Magenta as a Trianni Mouse licensee," commented Dr. David Meininger, Trianni's Chief Business Officer. "We are confident that The Trianni Mouse, with its complete human antibody repertoire and novel chimeric gene segment design, will quickly generate potent, highly developable leads in support of Magenta's biologics discovery efforts."
No financial details were disclosed.
About Trianni, Inc.
TRIANNI is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com
Chief Business Officer
Director of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trianni-signs-agreement-with-magenta-therapeutics-for-use-of-the-trianni-mouse-300427567.html
SOURCE Trianni, Inc.